98%
921
2 minutes
20
This study critically analyzes the findings of Geng , which investigated the association between continuous glucose monitoring (CGM) metrics and the risk of diabetic foot (DF) in individuals with type 2 diabetes mellitus. The study demonstrated significant associations between lower time in range, higher glycemic risk index, mean blood glucose, and time above range and an increased risk of DF. While acknowledging the study's strengths, such as its large sample size and robust statistical methods, this analysis also highlights its limitations, including its cross-sectional design and reliance on self-reported data. The findings are discussed within the framework of established theories, including the concepts of metabolic memory, the glucocentric paradigm, and the role of inflammation. This analysis emphasizes that a comprehensive approach to glucose management, extending beyond traditional glycated hemoglobin A1c measurements, is crucial for DF risk mitigation. Recognizing the impact of poor adherence and ongoing inflammation, future research should prioritize exploring causal mechanisms, the effectiveness of interventions aimed at improving CGM metrics, and the specific contributions of glucose variability to DF development. In conclusion, these findings strongly support the clinical application of diverse CGM metrics to enhance patient outcomes and effectively manage the risk of DF.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179890 | PMC |
http://dx.doi.org/10.4239/wjd.v16.i6.107006 | DOI Listing |
Diabetes Obes Metab
September 2025
Diabetes Care Unit, Nancy University Hospital, Nancy, France.
Aims: To assess the frequency and management of hypoglycaemia during unstructured physical activity (PA) in adults with type 1 diabetes (T1D) using automated insulin delivery (AID) systems in real-life settings.
Materials And Methods: RAPPID is a prospective, multicenter, observational study conducted over 1 month in four French tertiary care centres. Adults with T1D using one of three AID systems (MiniMed 780G, Tandem t:slim X2 with Control-IQ, or Ypsopump with CamAPS FX) and performing ≥2 unstructured PA sessions per week were included.
Diabet Med
September 2025
Edinburgh Centre for Endocrinology & Diabetes, NHS Lothian, Edinburgh, UK.
Aims: This study aimed to assess the impact of the Omnipod 5 automated insulin delivery (AID) system on continuous glucose monitoring (CGM) metrics, HbA1c, and weight in a real-world setting. Additionally, independent predictors of glycaemic response were assessed.
Methods: Observational analysis of adults with type 1 diabetes using Omnipod 5 (n = 353).
Diabetes Care
September 2025
Manchester Diabetes, Endocrine and Metabolism Centre, Manchester Royal Infirmary, Manchester University Hospitals National Health Service Foundation Trust, Manchester, U.K.
Diabetes Res Clin Pract
September 2025
Health Education Administration, and Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Background: Despite advances, glycemic control in people with type 2 diabetes (PwT2D) treated with oral antidiabetic medications (ADMs) often remains suboptimal. Continuous glucose monitoring (CGM) has shown promise in diabetes management, offering real-time insights into glucose trends. This study evaluates the impact of transitioning from conventional self-monitoring of blood glucose (SMBG) to CGM on glycemic outcomes and self-management in PwT2D receiving oral ADMs.
View Article and Find Full Text PDFDiabetes Technol Ther
September 2025